한빛사논문
- 조회683
Hye Won Jeong,1,2,12 Se-Mi Kim,3,12 Min Kyung Jung,4,12 Ji Yun Noh,5,12 Ji-Seung Yoo,3,12 Eun-Ha Kim,1 Young-Il Kim,3 Kwangmin Yu,1 Seung-Gyu Jang,1,3 Juryeon Gil,1 Mark Anthony Casel,1,3 Rollon Rare,1,3 Jeong Ho Choi,1 Hee-Sung Kim,1,2 Jun Hyoung Kim,2 Jihye Um,6 Chaeyoon Kim,4 Yeonjae Kim,7 Bum Sik Chin,7 Sungmin Jung,8 Jun Yong Choi,9 Kyoung-Ho Song,10 Yong-Dae Kim,1,11 Jun-Sun Park,6 Joon Young Song,5,* Eui-Cheol Shin,4,8,* and Young Ki Choi1,3,13,*
1College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju 28644, Republic of Korea
2Department of Internal Medicine, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea
3Center for Study of Emerging and Re-emerging Viruses, Korea Virus Research Institute, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
4The Center for Viral Immunology, Korea Virus Research Institute, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
5Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul 08308, Republic of Korea
6Public Health Research Institute, National Medical Center, Seoul 04564, Republic of Korea
7Division of Infectious Diseases, Department of Internal Medicine, National Medical Center, Seoul 04564, Republic of Korea
8Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea
9Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea
10Division of Infectious Diseases, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Republic of Korea
11Chungbuk Regional Cancer Center, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea
12These authors contributed equally
13Lead contact
*Correspondence
Abstract
Omicron has become the globally dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, creating additional challenges due to its ability to evade neutralization. Here, we report that neutralizing antibodies against Omicron variants are undetected following COVID-19 infection with ancestral or past SARS-CoV-2 variant viruses or after two-dose mRNA vaccination. Compared with two-dose vaccination, a three-dose vaccination course induces broad neutralizing antibody responses with improved durability against different SARS-CoV-2 variants, although neutralizing antibody titers against Omicron remain low. Intriguingly, among individuals with three-dose vaccination, Omicron breakthrough infection substantially augments serum neutralizing activity against a broad spectrum of SARS-CoV-2 variants, including Omicron variants BA.1, BA.2, and BA.5. Additionally, after Omicron breakthrough infection, memory T cells respond to the spike proteins of both ancestral and Omicron SARS-CoV-2 by producing cytokines with polyfunctionality. These results suggest that Omicron breakthrough infection following three-dose mRNA vaccination induces pan-SARS-CoV-2 immunity that may protect against emerging SARS-CoV-2 variants of concern.
논문정보
- Research article
- 2022년 10월 (BRIC 등록일 2022-11-04)
- 국내 연구진
- 의약학 > 감염의학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 논문보기
